Status:
COMPLETED
Association of Hydroxychloroquine, BRAF and MEK Inhibitors in Metastatic Melanoma : a Retrospective Case-control Study.
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Dermatology and Oncology
Eligibility:
All Genders
18+ years
Brief Summary
Patients with a BRAF mutated melanoma are usually treated in France by a first line of immunotherapy followed by a second line that combines a BRAF inhibitor (dabrafenib, vemurafenib, encorafenib) and...
Eligibility Criteria
Inclusion
- Patients with metastatic melanoma with an activating BRAF mutation
- Who received at least one line of immunotherapy
- Whose disease is resistant to a BRAF inhibitor used as a single agent or in combination with a MEK inhibitor
- Who received either cytotoxic chemotherapy or the combination dabrafenib + trametinib + hydroxychloroquine after disease progression to dabrafenib/trametinib from January 2008 to June 2020 in the Dermatology ward of the Lyon Sud Hospital
Exclusion
- Patients who did not received an immunotherapy prior to dabrafenib/trametinib treatment
- Absence of tumor board validation
Key Trial Info
Start Date :
January 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2020
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT04760080
Start Date
January 1 2019
End Date
October 1 2020
Last Update
February 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Lyon Sud
Pierre-Bénite, France, 69310